The global FMS-Like Tyrosine kinase 3 (FLT3) inhibitors market size was USD 405.6 Million in 2021 and is expected to register a revenue CAGR of 14.6% during the forecast period, according to latest analysis by Emergen Research. Rising high-value investments for Research & Development (R&D) initiatives by various major pharmaceutical companies for improvement in therapy tolerability and drugs is a key factor driving market revenue growth. In addition, rising incidences of Acute Myeloid Leukemia (AML) and relapse cases, growing number of potential pipeline drugs, and increasing approvals of new FLT3 inhibitor drugs by regulatory bodies are driving revenue growth of the FLT3 inhibitors market.
According to Novartis, AML accounts for approximately 25% of all adult leukemia and has lowest survival rate. FDA has now authorized three FLT3 inhibitors for use in the U.S. Midostaurin is approved for first-line treatment with chemotherapy, but gilteritinib is approved for R/R disease. Quizartinib and crenolanib are two new AML inhibitors in late-stage development for first-line and R/R treatment. Various advantages of improved targeted medicines, such as increased long-term survival rates, quality, and safety, are driving growth of the FLT3 inhibitors market.
Get a sample of the report @ https://www.emergenresearch.com/request-sample/1302
According to Cancer.net, the 5-year survival rate for individuals aged 20 years and older with AML is 27%, whereas it is 69% for individuals younger than 20. In addition, prognosis and survival of AML patients is strongly dependent on mutation profile and age. Lower survival rates are due to aging patient population’s unfavorable mutation profile mixed with their inability to tolerate intense therapy. Moreover, availability of medications with effectiveness and minimal toxicity, as well as oral formulations, is driving demand for FLT3 inhibitors, specifically among elderly and weak patients.
The latest market intelligence report, titled ‘Global FMS Like Tyrosine kinase 3 inhibitors Market’, is intended to provide the target audience with the necessary information about the global FMS Like Tyrosine kinase 3 inhibitors Market industry. The report comprises a detailed analysis of the vital elements of the FMS Like Tyrosine kinase 3 inhibitors Market, including key drivers, constraints, opportunities, limitations, threats, and micro-and macro-economic factors. The report carefully investigates the present market scenario and the fundamental growth prospects. The report entails an organized database of the FMS Like Tyrosine kinase 3 inhibitors Market dynamic that helps market analysts estimate the global market growth rate over the projected timeline.
Key players include:
Astellas Pharma Inc., Novartis AG, Pfizer Inc., Daiichi Sanyo Company, Limited, Cullinan Oncology, Inc., AROG Pharmaceuticals, Inc., Aptose Biosciences Inc., FUJIFILM Pharmaceuticals U.S.A., Inc., CSPC Pharmaceutical Group Limited, and Allarity Therapeutics, Inc.
To know more about the report @ https://www.emergenresearch.com/industry-report/fms-like-tyrosine-kinase-3-inhibitors-market
Emergen Research has segmented the global FLT3 inhibitors market based on drug type, therapies, and region:
Drug Type Outlook (Revenue, USD Million; 2019-2030)
Midostaurin
Gilteritinib
Sorafenib
Therapies Outlook (Revenue, USD Million; 2019-2030)
Type 1 FLT3 inhibitors
Type 2 FLT3 inhibitors
Regional Analysis:
This section of the report offers valuable insights into the geographical segmentation of the FMS Like Tyrosine kinase 3 Inhibitors market, alongside estimating the current and future market valuations based on the demand-supply dynamics and pricing structure of the leading regional segments. Furthermore, the growth prospects of each segment and sub-segment have been meticulously described in the report.
The report classifies the global FMS Like Tyrosine kinase 3 Inhibitors market into various regions, including:
North America (U.S., Canada)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Europe (U.K., Italy, Germany, France, Rest of EU)
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Middle East & Africa (Saudi Arabia, the U.A.E., South Africa, Rest of MEA)
Key Questions Answered in the Report:
What will be the estimated growth rate of the FMS Like Tyrosine kinase 3 inhibitors market by 2030?
Who are the prominent distributors, vendors, and manufacturers of the market?
What are the driving and restraining factors of the growth of the FMS Like Tyrosine kinase 3 inhibitors market throughout the forecast period?
What are the current and future market trends of the FMS Like Tyrosine kinase 3 inhibitors market?
What are the sales and price analysis of the product by types, applications, and regions?
What are the expected opportunities for the companies and new entrants in the coming years?
Thank you for reading the research report. To get more information about the customized report and customization plan, kindly connect to us and we will provide you with the well-suited customized report.
About Us:
At Emergen Research, we believe in advancing with technology. We are growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
